# Lainie P. Martin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lainie-p-martin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,640 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 41 |
| i10-index | 75 |
| Last Known Institution | Argosy University |
| OpenAlex ID | https://openalex.org/A5089503365 |
| ORCID iD | 0000-0002-3802-015X |
| Works | 282 |

## Researcher papers

- [Platinum Resistance: The Role of DNA Repair Pathways](https://scholariq.org/papers/platinum-resistance-the-role-of-dna-repair-pathways/)
- [Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-2-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer](https://scholariq.org/papers/mirvetuximab-soravtansine-in-fr-positive-platinum-resistant-ovarian-cancer/)
- [NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022](https://scholariq.org/papers/nccn-guidelines-insights-ovarian-cancer-version-3-2022/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)
- [Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)
- [Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study](https://scholariq.org/papers/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha/)
- [First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-study-of-amg-820-a-monoclonal-anti-colony-stimulating-factor-1/)
- [Ovarian Cancer, Version 3.2012](https://scholariq.org/papers/ovarian-cancer-version-3-2012/)
- [Uterine Neoplasms, Version 1.2014](https://scholariq.org/papers/uterine-neoplasms-version-1-2014/)
- [Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study](https://scholariq.org/papers/rucaparib-maintenance-for-newly-diagnosed-advanced-ovarian-cancer-interim/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Researcher university

- [Argosy University](https://scholariq.org/institutions/argosy-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.